Detail

Basic Information Clinical Results Relationship Graph

Basic Information

Gene symbol	BIRC5	Synonyms	API4, EPR-1	Type of gene	protein-coding
Chromosome	17	Map location	17q25.3	dbXrefs
Description	baculoviral IAP repeat containing 5

Gene symbol	CTAG1B	Synonyms	CT6.1, CTAG, CTAG1, ESO1, LAGE-2, LAGE2B, NY-ESO-1	Type of gene	protein-coding
Chromosome	X	Map location	Xq28	dbXrefs
Description	cancer/testis antigen 1B

Gene symbol	MAGEC1	Synonyms	CT7, CT7.1	Type of gene	protein-coding
Chromosome	X	Map location	Xq27.2	dbXrefs
Description	MAGE family member C1

Gene symbol	MAGEC2	Synonyms	CT10, HCA587, MAGEE1	Type of gene	protein-coding
Chromosome	X	Map location	Xq27.2	dbXrefs
Description	MAGE family member C2

Gene symbol	MUC1	Synonyms	ADMCKD, ADMCKD1, ADTKD2, CA 15-3, CD227, Ca15-3, EMA, H23AG, KL-6, MAM6, MCD, MCKD, MCKD1, MUC-1, MUC-1/SEC, MUC-1/X, MUC1/ZD, PEM, PEMT, PUM	Type of gene	protein-coding
Chromosome	1	Map location	1q22	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas
Description	mucin 1, cell surface associated

Gene symbol	TPBG	Synonyms	5T4, 5T4AG, M6P1, WAIF1	Type of gene	protein-coding
Chromosome	6	Map location	6q14.1	dbXrefs
Gene perturbation-related omics dataset	PerturbAtlas \| PertOrg
Description	trophoblast glycoprotein

GTO ID	GTC0374
Trial ID	NCT03164772
Disease	Lung Non-Small Cell Carcinoma
Altered gene	MUC1\|BIRC5\|CTAG1B\|TPBG\|MAGE-C2\|MAGE-C1
Therapeutic/Target gene	Therapeutic gene
Therapy	mRNA vaccine
Treatment	BI 1361849\|CV9202
Co-treatment	Durvalumab\|Tremelimumab\|PharmaJet Tropis device
Phase	Phase1\|Phase2
Recruitment status	Completed
Title	A Phase 1/2 Study of Combination Immunotherapy and mRNA Vaccine in Subjects With Non-small Cell Lung Cancer (NSCLC)
Year	2017
Country	United States
Company sponsor	Ludwig Institute for Cancer Research
Other ID(s)	LUD2014-012-VAC

Clinical Result

Cohort1: Durvalumab_PharmaJet Tropis device

Administration route	intradermal injection\|intravenous infusion
Dosage	BI 1361849, 100 µL (80 µg), 14 doses over the 12 cycles
Pts	23
Age	Adult, Older_Adult
Adverse reactions	12/23(All-cause mortality); 14/23(Cardiac disorders; Eye disorders; Gastrointestinal disorders; General disorders; Infections and infestations; Injury, poisoning and procedural complications; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Respiratory, thoracic and mediastinal disorders; Surgical and medical procedures; Vascular disorders)

Cohort2: Durvalumab_Tremelimumab_PharmaJet Tropis device

Administration route	intradermal injection\|intravenous injection
Dosage	BI 1361849, 100 µL (80 µg), 14 doses over the 12 cycles
Pts	34
Age	Adult, Older_Adult
Adverse reactions	22/34(All-cause mortality); 22/34(Cardiac disorders; Gastrointestinal disorders; General disorders; Infections and infestations; Injury, poisoning and procedural complications; Metabolism and nutrition disorders; Musculoskeletal and connective tissue disorders; Neoplasms benign, malignant and unspecified(incl cysts and polyps); Nervous system disorders; Renal and urinary disorders; Respiratory, thoracic and mediastinal disorders; Vascular disorders)

Relationship Graph

Overview of Knowledge Graph